

Standard operating procedure

Title: Preparation, dissemination and publication of safety-related EMA press releases and questionand-answer documents

Status: PUBLIC		Document no.: SOP/EMA/0111	
Lead author	Approver	Effective date: 12-APR-11	
Name: Sabine Haubenreisser	Name: Andreas Pott	Review date: 12-APR-14	
Signature: ON FILE	Signature: ON FILE	Supersedes:	
		N/A	
Date: 14-FEB-11	Date: 12-APR-11	TrackWise record no.: 1746	

1. Purpose

To ensure that the Agency prepares and publishes safety-related press releases and question-andanswer documents in a timely and consistent manner, and disseminates this information within the EU regulatory network (EMA, NCAs and EC) and to international partners prior to publication.

This SOP does not cover communication through other communication tools such as CHMP press release and CHMP monthly report.

2. Scope

This SOP applies to the Human Medicines Development and Evaluation Unit, the Patient Health and Protection Unit and the Office of the Executive Director.

3. Responsibilities

It is the responsibility of each Head of Sector to ensure that this procedure is adhered to within his or her sector. The responsibility for the execution of each step of this procedure is identified in the righthand column of Heading **9. Procedure**.

Depending on time constraints during this procedure, steps can be merged or timelines adjusted on a case-by-case basis. In exceptional cases timing will also depend on a possible co-ordination with international authorities.

As the documents described in this procedure [i.e. press releases (PRs) and question-and-answer documents (Q&As)] are European Medicines Agency (EMA) documents, the ultimate responsibility for their wording and content lies with the Agency. However, consensus should be sought from all parties



An agency of the European Union

 \odot European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged.

⁷ Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom **Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8416 **E-mail** info@ema.europa.eu **Website** www.ema.europa.eu

concerned wherever possible, and all views and comments received from the various parties involved will be taken into account during the preparation of the documents.

The Office of the Executive Director is responsible for the preparation, sign-off and publication of press releases and for the publication of question-and-answer documents while the Medical Information Sector is responsible for the preparation and sign-off of the question-and-answer documents. The Medical Information Sector is also responsible for the dissemination of the press releases and question-and-answer documents within the EU regulatory network (EMA, NCAs and EC) and to international partners prior to publication.

4. Changes since last revision

New SOP.

5. Documents needed for this SOP

Templates for EMA PRs and Q&As, templates for sending the draft documents to the Committee for Medicinal Products for Human Use (CHMP) and Pharmacovigilance Working Party (PhVWP), and the web content transmission slip used for this SOP are available in Microsoft Word under File/New and can be found on the X: drive in the 'templates' folder.

6. Related documents

SOP/T/1040 - Publication of documents produced by the EMA

WIN/H/3210 – Sending of lines to take and safety-related information to the European Union regulatory network and international partners

SOP/H/3346 - Early Notification System: procedure for advanced notification of emerging safety issues to EU regulatory network and international partners

SOP/H/3347 – Preparation of 'lines-to-take' documents for use within the EU regulatory network to answer external queries in a consistent manner

Principles of EMEA press release (EMA/213289/2007)

Procedure for review of information on products by patients'/consumers' organisations (EMA/279083/06)

European Medicines Agency Communication on (emerging) safety related issues for medicines for human use – practical arrangements (EMA/785792/2009)

Policy on European Medicines Agency communication on (emerging) safety related issues for medicines for human use (EMA/170165/2010)

The European Union regulatory system incident management plan for medicines for human use (for use in the context of a pilot) (EMEA/579383/2008).

WIN/EMA/0031 - Sending of press releases

7. Definitions


CAP: Centrally authorised medicinal product


CoRapp: Co-rapporteur


CHMP:	Committee for Medicinal Products for Human Use
D-ED:	Office of the Executive Director
D-ED-COM:	Communications and Media
DREAM:	Document Records Electronic Archive Management
EC:	European Commission
EMA:	European Medicines Agency
ENS:	Early Notification System
EU:	European Union
HMA-H:	Heads of Medicines Agencies - Human
HoS:	Head of Sector
HoU:	Head of Unit
IRN:	Incidence Review Network
LTTs:	Lines to take
MA:	Marketing authorisation
MAH:	Marketing authorisation holder
MedW:	Medical writer
NCA:	National competent authority
NAP:	Nationally authorised medicinal product
Ρ:	Patient Health Protection Unit
P-MI:	Medical Information Sector
P-MI-PIN	Section for Public Information and Stakeholder Networking
H-SE:	Safety and Efficacy of Medicines Sector
P-PV:	Pharmacovigilance and Risk Management Sector
PhVWP:	Pharmacovigilance Working Party
POM:	Product Oversight Meeting
P-R	Regulatory, Procedural and Committee Support Sector
PR:	Press release
PTL:	Product team leader
PTL Sec:	Product team leader's secretary
PTM:	Product team member
Q&A:	Question-and-answer document
Rapp:	Rapporteur
SH:	Section Head


- SOP: Standard operating procedure
- WIN: Work instructions


8. Process map(s)/ flow chart(s)











9. Procedure

Step	Action	Responsibility
1	 Identify safety issues that may require communication (as proposed in the Policy on European Medicines Agency communication on (emerging) safety related Issues for medicines for human use (EMA/170165/2010)) or receive information on safety issues as identified by the IRN. As a guide, the following types of safety issues should be included: Suspension, withdrawal or revocation of a marketing authorisation for safety reasons; Start or finalisation of a community referral or review procedure initiated for safety reasons (e.g. article 5(3), 20, 31 or 107); New safety information such as new contraindications, warnings or undesirable effects; Supply shortages; Product defects that may lead to safety concerns; Any other emerging safety concerns that may give rise to media interest. 	PTL
2	Is the issue or concern to be discussed at the next CHMP meeting? If yes go to 3; If no go to 50.	PTL
	The safety issue or concern is to be discussed at the next CHMP meeting	
3	Add safety issue to the Early Notification System table in line with the SOP/3346, and inform Rapp and CoRapp.	PTL
4	Unless the IRN has taken a decision before, ensure that during the POM that takes place on Tuesday prior to the CHMP, a decision is made on whether the Agency will communicate and which communication tools will be used (i.e. PR, Q&A or LTTs).	PTL
	If LTTs are considered necessary, follow the separate SOP on LTTs (SOP/H/3347).	
	If a Q&A is needed, nominate MedW responsible from P-MI-PIN and inform the PTL accordingly.	SH P-MI-PIN
	If a PR is needed, nominate person responsible from D-ED-COM and inform the PTL accordingly.	D-ED-COM
	Ensure that tentative embargo for publication is agreed (usually Thursday of the CHMP week at 16:00h UK time).	D-ED-COM
5	Inform the CHMP Chair about the upcoming communication during the teleconference with Chair and Vice-chair. This usually takes	PTL

_

Step	Action	Responsibility
	place on the Thursday prior to CHMP week.	
6	Send the Early Notification System table to HMA-H, EC, CHMP, PhVWP and international partners (in accordance with WIN/H/3210) to inform them about the upcoming potential communication by Thursday prior to CHMP week.	P-MI sec
7	Ensure in collaboration with the CHMP secretariat that safety issues included in the Early Notification System are scheduled for discussion on Monday of CHMP meeting.	PTL
8	Organise a meeting with PTL and other concerned staff to determine the key messages.	MedW/ or D-ED- COM
9	Identify experts from eligible patient/consumer organisations to be involved in the review, when possible.	P-MI-PIN
10	Prepare first draft of the PR.	D-ED-COM
11	Prepare first draft of the Q&A.	MedW
12	Send first draft of the PR for internal review to relevant EMA staff (PTL, PTM and P-MI).	D-ED-COM
13	Send first draft of the Q&A for internal review to relevant EMA staff (PTL, PTM and D-ED-COM).	MedW
14	Implement comments on the PR as appropriate.	D-ED-COM
15	Implement comments on the Q&A as appropriate.	MedW
16	Send the updated PR to the Rapp and CoRapp for comment.	D-ED-COM
17	Send the updated Q&A to the Rapp and CoRapp for comment.	MedW
18	Implement comments from Rapp and CoRapp on the PR as appropriate.	D-ED-COM
19	Implement comments from Rapp and CoRapp on the Q&A as appropriate.	MedW
20	Ensure in collaboration with the CHMP secretariat that the safety issue is discussed on Monday of the CHMP week and that the PR and/or Q&A are discussed by Wednesday morning.	PTL
21	Amend the PR in line with the CHMP discussion and the expected final opinion/outcome of the CHMP's deliberations.	D-ED-COM
22	Amend the Q&A in line with the CHMP discussion and the expected final opinion/outcome of the CHMP's deliberations.	MedW
23	Send the amended Q&A to the PhVWP contact point and the amended Q&A (and amended PR as appropriate) to the patient/consumer organisation (selected at step 9).	P-MI-PIN
24	Implement comments on the Q&A from PhVWP and	MedW

Step	Action	Responsibility
	patient/consumer organisation as appropriate, liaising with PTL as necessary.	
25	Implement comments on the PR from the PhVWP and patient/consumer organisation as appropriate, liaising with PTL as necessary.	D-ED-COM
26	Send updated PR to PTL.	D-ED-COM
27	Send updated Q&A to PTL.	MedW
28	Table documents for discussion at CHMP plenary meeting, no later than Wednesday morning of the CHMP week, and inform D-ED- COM and P-MI-PIN when the topic is to be discussed.	PTL
29	Present PR to CHMP, if necessary, no later than Wednesday morning, noting comments.	D-ED-COM
30	Present Q&A to CHMP, if necessary, no later than Wednesday morning, noting comments.	MedW
31	Implement comments on PR from CHMP as appropriate, liaising with PTL as necessary. Ensure that the information in the PR and Q&A is aligned.	D-ED-COM
32	Implement comments on Q&A from CHMP as appropriate, liaising with PTL as necessary. Ensure that the information in the PR and Q&A is aligned.	MedW
33	Send updated Q&A to the MAH(s) for information, if feasible. Only factual corrections suggested by the MAH(s) can be accepted.	MedW
34	Send updated PR to the MAH(s) for information, if feasible. Only factual corrections suggested by the MAH(s) can be accepted.	PTL
35	Perform an editorial quality check of the PR (e.g. check spelling and grammar).	D-ED-COM
36	Perform an editorial quality check of the Q&A (e.g. check spelling and grammar).	MedW
37	Send final version of the PR to PTL, copying in PTM, SH, P-MI Sec and other concerned EMA staff. Indicate the timing for publication. No additional changes are possible at this time.	D-ED-COM
38	Send final version of the Q&A to PTL, copying in PTM, SH, P-MI Sec and other concerned EMA staff. Indicate the timing for publication. No additional changes are possible at this time.	MedW
39	Circulate final version of PR and Q&A to CHMP for information.	PTL
40	Send final documents (Q&A and/or PR) to HMA-H, EC, CHMP, PhVWP and international partners and inform EMA concerned staff	P-MI Sec

_

Step	Action	Responsibility
	in accordance with WIN/H/3210.	
41	Once adopted by the CHMP and no later than the evening prior to the day of publication, book-mark and PDF final product information and send to P-MI-PIN, if publication of the product information is foreseen at this stage.	PTL sec
42	Prepare sign-off for PR, convert it into PDF format and save it in G-drive (G:\External Information Draft\SIGN OFF\Directorate) for web publication. Specify the location of the file on the transmission slip.	D-ED-COM
43	Prepare sign-off for Q&A, convert it into PDF format and save in G-drive (G:\External Information Draft\SIGN OFF\Human Unit\Safety Q&A) for web publication. Specify the location of the file on the transmission slip.	P-MI Sec
44	Sign-off PR for publication.	D-ED-COM
45	Sign-off Q&A for publication.	HoS P-MI
46	Publish documents on the EMA external web site at the agreed embargo date and time.	Web team
47	Send the PR to the press group (WIN/EMA/0031).	D-ED-COM
48	Send a link to the published documents to the patient/consumer organisation involved.	P-MI-PIN
49	File original transmission slips.	Web team
	The safety issue needs to be addressed before the next CHMP meeting	
50	Inform the SH, HoU P, HoS P-R, HoS P-MI, D-ED-COM, HoS P-PV, Rapp and CoRapp. If necessary, make sure that an ad hoc POM will take place.	PTL
51	Ensure in collaboration with HoU P, HoS P-MI and HoS D-ED that a decision is made on whether the Agency will communicate and which communication tools will be used (i.e. PR, Q&A or LTTs).	PTL
	If LTTs are considered necessary, follow the separate SOP on LTTs (SOP/H/3347).	
	If a Q&A is needed, nominate MedW responsible from P-MI-PIN and inform the PTL accordingly.	SH P-MI-PIN
	If a press release is needed, nominate person responsible from D-ED-COM and inform the PTL accordingly.	D-ED-COM
	Ensure that embargo for publication is agreed.	D-ED-COM
52	Inform the CHMP Chair about the upcoming communication.	PTL

Step	Action	Responsibility
53	Organise a meeting with PTL and other concerned staff to determine the key messages.	MedW/ or D-ED- COM
54	Identify experts from eligible patient/consumer organisations to be involved in the review, when possible.	P-MI-PIN
55	Prepare first draft of the PR.	D-ED-COM
56	Prepare first draft of the Q&A.	MedW
57	Send first draft of the PR for internal review to relevant EMA staff (PTL, PTM and P-MI).	D-ED-COM
58	Send first draft of the Q&A for internal review to relevant EMA staff (PTL, PTM and D-ED-COM).	MedW
59	Implement comments on the PR as appropriate.	D-ED-COM
60	Implement comments on the Q&A as appropriate.	MedW
61	Send the updated PR to the Rapp and CoRapp for comment.	D-ED-COM
62	Send the updated Q&A to the Rapp and CoRapp for comment.	MedW
63	Implement comments from Rapp and CoRapp on the PR as appropriate.	D-ED-COM
64	Implement comments from Rapp and CoRapp on the Q&A as appropriate.	MedW
65	Send the draft documents to the CHMP, PhVWP contact point (if applicable) and patient/consumer organisation (selected in step 54) for comments, highlighting the embargo.	P-MI Sec
66	Implement comments on PR from CHMP, PhVWP and patient/consumer organisation as appropriate, liaising with PTL as necessary. Ensure that the information in the PR and Q&A is aligned.	D-ED-COM
67	Implement comments on Q&A from CHMP, PhVWP and patient/consumer organisation as appropriate, liaising with PTL as necessary. Ensure that the information in the PR and Q&A is aligned.	MedW
68	Send updated Q&A to the MAH(s) for information, if feasible. Only factual corrections suggested by the MAH(s) can be accepted.	MedW
69	Send updated PR to the MAH(s) for information, if feasible. Only factual corrections suggested by the MAH(s) can be accepted.	PTL
70	Perform an editorial quality check of the PR (e.g. check spelling and grammar).	D-ED-COM
71	Perform an editorial quality check of the Q&A (e.g. check spelling and grammar).	MedW

Step	Action	Responsibility
72	Send final version of the PR to PTL, copying in PTM, SH, P-MI Sec and other concerned EMA staff. Indicate the timing for publication. No additional changes are possible at this time.	D-ED-COM
73	Send final version of the Q&A to PTL, copying in PTM, SH, P-MI Sec and other concerned EMA staff. Indicate the timing for publication. No additional changes are possible at this time.	MedW
74	Send final documents (Q&A and/or PR) to HMA-H, EC, CHMP, PhVWP and international partners and inform EMA concerned staff in accordance with WIN/H/3210.	P-MI Sec
75	No later than the evening prior to the day of publication, book- mark and PDF final product information and send to P-MI-PIN, if publication of the product information is foreseen at this stage.	PTL sec
76	Prepare sign-off for PR, convert it into PDF format and save it in G- drive (G:\External Information Draft\SIGN OFF\Directorate) for web publication. Specify the location of the file on the transmission slip.	D-ED-COM
77	Prepare sign-off for Q&A, convert it into PDF format and save in G- drive (G:\External Information Draft\SIGN OFF\Human Unit\Safety Q&A) for web publication. Specify the location of the file on the transmission slip.	P-MI Sec
78	Sign-off PR for publication.	D-ED-COM
79	Sign-off Q&A for publication.	HoS P-MI
80	Publish documents on the EMA external web site at the agreed embargo date and time.	Web team
81	Send the PR to the press group (WIN/EMA/0031).	D-ED-COM
82	Send a link to the published documents to the patient/consumer organisation involved.	P-MI-PIN
83	File original transmission slips.	Web team

10. Records

Original EMA PR, Q&A and correspondence are filed in the Master File. Electronic copies are saved in DREAM.